Page last updated: 2024-10-30

leflunomide and Carcinoma, Renal Cell

leflunomide has been researched along with Carcinoma, Renal Cell in 1 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Carcinoma, Renal Cell: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, Y1
Huang, Q1
Zhou, H1
Wang, Y1
Hu, X1
Li, T1

Other Studies

1 other study available for leflunomide and Carcinoma, Renal Cell

ArticleYear
Inhibition of canonical WNT/β-catenin signaling is involved in leflunomide (LEF)-mediated cytotoxic effects on renal carcinoma cells.
    Oncotarget, 2016, Aug-02, Volume: 7, Issue:31

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; beta Catenin; Carcinoma, Renal Cell; Cell Line

2016